Investigates IOP-1's effect on non-small cell lung cancer, suggesting a novel treatment approach.
INTRODUCTION: The aim of this study was to investigate the antitumor effect of IOP-1 on non-small cell lung cancer (NSCLC) and its mechanism Materials: We isolated and purified an acidic polysaccharide component from Inonotus obliquus, identified its specific functional groups and monosaccharide composition, and named it IOP-1. We studied the mechanism of IOP-1 on non-small cell lung cancer through a series of in vitro experiments and measured relevant indicators in in vivo experiments. Through the results of both in vivo and in vitro experiments, we explored the mechanism of action and antitumor effects of IOP-1 in non-small cell lung cancer. RESULTS: We isolated and purified an acidic polysaccharide component from Inonotus obliquus, identified its specific functional groups and monosaccharide composition, and named it IOP-1. Studies found that IOP-1 can inhibit the proliferation and migration of NCI-H460 cells and induce their apoptosis. When IOP-1 was applied to NCI-H460 cells, the expression of Bax, Bcl-2, MMP-9, and Parp-1 decreased, while the expression of P53 and Cyto-c increased. Experiments in mice showed that IOP-1 can effectively inhibit tumor growth, increase spleen weight, and reduce blood perfusion in mice. Compared with the model group, dietary conditions improved. DISCUSSION: IOP-1 has significant antitumor activity against NCI-H460 cells, inhibiting the growth and migration of non-small cell lung cancer by regulating apoptosis and migration-related pathways. CONCLUSIONS: As a new drug, IOP-1 provides a new method for the clinical treatment of non-small cell lung cancer.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: